Lv4
484 积分 2024-09-27 加入
Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial
1天前
待确认
Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
1天前
已完结
Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial
1个月前
已完结
Efficacy and safety of once weekly semaglutide 2·4 mg for weight management in a predominantly east Asian population with overweight or obesity (STEP 7): a double-blind, multicentre, randomised controlled trial
1个月前
已完结
Urine Albumin-Creatinine Ratio Variability in People With Type 2 Diabetes: Clinical and Research Implications
1个月前
已完结
A randomized phase I study of BI 1820237, a novel neuropeptide Y receptor type 2 agonist, alone or in combination with low‐dose liraglutide in otherwise healthy men with overweight or obesity
1个月前
已完结
Safety and efficacy of an extended‐release peptide YY analogue for obesity: A randomized, placebo‐controlled, phase 1 trial
1个月前
已完结
Obesity: Epidemiology, Pathophysiology, and Therapeutics
1个月前
已完结
A phase 2, adaptive randomized, double-blind, placebo-controlled, multicenter, 52-week study of HM15211 in patients with biopsy-confirmed non-alcoholic steatohepatitis – Study design and rationale of HM-TRIA-201 study
3个月前
已完结
[Guidelines for the prevention and treatment of metabolic dysfunction-associated (non-alcoholic) fatty liver disease (Version 2024)]
4个月前
已完结
皖公网安备34019202002308
